Product Description & Research Overview

SLU-PP-332 is a synthetic Pan-ERR (estrogen-related receptor) agonist originally developed at Saint Louis University and classified as an exercise mimetic. Rather than acting as a stimulant, hormone, or GLP-1 receptor agonist, it activates many of the same metabolic pathways normally stimulated during endurance exercise by enhancing mitochondrial function and cellular energy production.

By activating ERRα, ERRβ, and ERRγ, SLU-PP-332 stimulates PGC-1α and AMPK signaling, leading to increased mitochondrial biogenesis, enhanced fatty acid oxidation, improved ATP production, and greater metabolic flexibility. Preclinical studies have demonstrated improvements in endurance capacity, insulin sensitivity, body composition, oxidative metabolism, and mitochondrial health without requiring increased physical activity.

Animal research has reported approximately 12% body-weight reduction over 28 days while preserving lean mass, along with increases in mitochondrial density of up to 1.8-fold. The compound also shows strong selectivity for ERRα, making it a unique approach to improving metabolic efficiency at the cellular level.

Researchers continue to investigate SLU-PP-332 for its potential role in obesity, metabolic syndrome, fatty liver disease, age-related mitochondrial decline, endurance performance, and healthy aging. Current evidence comes primarily from preclinical animal studies, and although early findings are promising, human clinical research remains limited. SLU-PP-332 remains an investigational compound with no approved therapeutic indication.